Das A, Zhou X, Metz SW, Vink MA, Berkhout B. Selecting the optimal Tet-on system for doxycycline-inducible gene expression in transiently transfected and stably transduced mammalian cells. Biotechnol J. 2016;11:71–9.

Article  CAS  PubMed  Google Scholar 

Gossen M, Bujard H. Tetracyclines in the control of gene expression in eukaryotes. In: Nelson M, Hillen W, Greenwald RA, editors. Tetracyclines in biology. Chemistry and medicine, Birkhäuser Verlag: Basel CH; 2001. p. 139–57.

Chapter  Google Scholar 

Baron U, Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol. 2000;327:401–21.

Article  CAS  PubMed  Google Scholar 

Berens C, Hillen W. Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur J Biochem. 2003;70:3109–21.

Article  Google Scholar 

Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992;89:5547–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268(5218):1766–9.

Article  CAS  PubMed  Google Scholar 

Mohammadi S, Alvarez-Vallina L, Ashweorth LJ, Hawkins RE. Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues. Gene Ther. 1997;4:993–7.

Article  CAS  Google Scholar 

Brader P, Serganova I, Blasberg RG. Noninvasive molecular imaging using reporter genes. J Nucl Med. 2013;54:167–72.

Article  CAS  PubMed  Google Scholar 

Soldatov A, von Klot CAJ, Walacides D, Derlin T, et al. Patterns of progression after 68Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):95–104.

Article  PubMed  Google Scholar 

Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and radionuclide therapy in prostate cancer. Semin Nucl Med. 2016;46(6):522–35.

Article  PubMed  PubMed Central  Google Scholar 

Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. PET/CT With 68Ga-PSMA in prostate cancer: radiopharmaceutical background and clinical implications. Curr Radiophar. 2018;11(1):4–13.

Article  CAS  Google Scholar 

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17.

Article  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016;11:1177–88.

Article  Google Scholar 

Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117–36.

Article  PubMed  Google Scholar 

Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22(1):9–15.

Article  CAS  PubMed  Google Scholar 

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, et al. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(9):1911–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seifert R, Schafigh D, Bögemann M, Weckesser M, Rahbar K. Detection of local relapse of prostate cancer with 18F-PSMA-1007. Clin Nucl Med. 2019;44(6):e394–5.

Article  PubMed  Google Scholar 

Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, et al. Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm. 2018;15(11):5183–91.

Article  CAS  PubMed  Google Scholar 

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.

Article  CAS  PubMed  Google Scholar 

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57(Suppl 3):79S-89S.

Article  CAS  PubMed  Google Scholar 

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):987–8.

Article  PubMed  Google Scholar 

Pillai AMR, Knapp FFRJR, et al. Lutetium-177 labeled therapeutics: 177Lu-PSMA is set to redefine prostate cancer treatment. Curr Radiopharm. 2016;9(1):6–7.

Article  CAS  PubMed  Google Scholar 

Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhof CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477–88.

Article  PubMed  PubMed Central  Google Scholar 

Das T, Guleria M, Parab A, Kale C, Shah H, Sarma HD, et al. Clinical translation of (177)Lu-labeled PSMA-617: initial experience in prostate cancer patients. Nucl Med Biol. 2016;43(5):296–302.

Article  CAS  PubMed  Google Scholar 

Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin. 2016;55(3):123–8.

Article  PubMed  Google Scholar 

Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18–28.

Article  PubMed  Google Scholar 

Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5):552–8.

Article  CAS  PubMed  Google Scholar 

Heston WD. Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase. Urologe A. 1996;35(5):400–7.

Article  CAS  PubMed  Google Scholar 

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.

CAS  PubMed  Google Scholar 

Bařinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19(6):856–70.

Article  PubMed  PubMed Central  Google Scholar 

Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, et al. Evaluation of prostate-specific membrane antigen as an imaging reporter. J Nucl Med. 2014;55:805–11.

Article  CAS  PubMed  Google Scholar 

Simons BW, Turtle NF, Ulmert DH, Abou DS, Thorek DLJ. PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool. Prostate. 2019;79(6):678–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmittgen TD, Zakrajsek BA, Hill RE, Liu Q, Reeves JJ, Axford PD, Singer MJ, Reed MW. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model. Prostate. 2003;55(4):308–16.

Article  CAS  PubMed  Google Scholar 

Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Weiner DB. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunol Immunother. 2017;66(12):1577–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiu D, Tavaré R, Haber L, Aina OH, Vaz